Cas:65686-95-5 2,2,2-trifluoro-1-thiophen-2-ylethanamine manufacturer & supplier

Chemical Name:2,2,2-trifluoro-1-thiophen-2-ylethanamine

CAS.NO:65686-95-5

Synonyms:2,2,2-trifluoro-1-(thiophen-2-yl)ethanamine;a8899

Molecular Formula:C₆H₆F₃NS

Molecular Weight:181.17900

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:208.9ºC at 760 mmHg

Density:1.366g/cm3

Index of Refraction:1.487

PSA:54.26000

Exact Mass:181.01700

LogP:3.01050

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2,2,2-trifluoro-1-(thiophen-2-yl)ethanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,a8899 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,2,2-trifluoro-1-(thiophen-2-yl)ethanamine Use and application,a8899 technical grade,usp/ep/jp grade.

Related News: FT was defined as any difficulty paying medical bills, high financial distress, cost-related medication nonadherence, food insecurity, and/or foregone/delayed care due to cost. 2,2,2-trifluoro-1-thiophen-2-ylethanamine manufacturer For both Black and white women, younger age and ER-negative breast cancer were risk factors in the genes most strongly associated with breast cancer, including BRCA1, BRCA2 and PALB2. 2,2,2-trifluoro-1-thiophen-2-ylethanamine supplier One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 2,2,2-trifluoro-1-thiophen-2-ylethanamine vendor For both Black and white women, younger age and ER-negative breast cancer were risk factors in the genes most strongly associated with breast cancer, including BRCA1, BRCA2 and PALB2. 2,2,2-trifluoro-1-thiophen-2-ylethanamine factory One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively.